The Biden administration is moving to reclassify cannabis as a Schedule III drug, which would remove the plant from the “most dangerous” list and recognize that it has medical uses.
The Biden administration is working towards reclassifying cannabis as a Schedule III drug. If this is successful, cannabis will no longer be considered as one of the "most dangerous" drugs, and its medical benefits will be recognized.
Kristian Foden-Vencil / OPB
Portland attorney Amy Margolis sees the move as a way to get much-needed research on cannabis, but it could also pave the way for big pharmaceutical companies to get involved in the established industry in Oregon.
Amy Margolis is a Portland attorney specializing in cannabis law and policy.
Courtesy Amy Margolis
“They’re the ones who will be legally operating if they follow the final rules produced by the FDA and the standard FDA approval and sales process for pharmaceuticals,” Margolis says. “It certainly injects a concern that now we have real big pharmaceutical interests involved in the cannabis market.”
Margolis runs Margolis Legal, a Portland law firm that works with clients in the cannabis industry. She says this proposal doesn’t do what many in the industry have been advocating for; removal of cannabis from the schedule of illegal drugs entirely.
“I think it’s a remnant of the drug war, " she says. “I think it’s kind of outdated perspectives on cannabis being a hard drug.”
Margolis spoke with OPB “All Things Considered” host Geoff Norcross:
Geoff Norcross: Basically speaking, the Biden administration is saying they want to officially recognize that cannabis is not as dangerous as the most dangerous drugs. Isn’t that a good thing?
Amy Margolis: Theoretically, that’s a good thing. We’ve long known that cannabis is not dangerous, should be treated like alcohol, which this does not do. But in theory, yes, that’s a good thing. How it impacts the market? We’re not so sure.
Norcross: Okay, what could happen?
Margolis: So what this did is it sent over the reclassification recommendation to the FDA to essentially rule make around it. And from my perspective, and I think the perspective of many of my peers, this simply opened up a pathway for pharmaceutical companies to get involved in the cannabis industry, whether through the development and sales of pharmaceutical cannabis or through the research component.
Norcross: And what would that mean for the local market, which doesn’t have a lot of big players like the pharmaceutical industry in it?
Margolis: Other than the DOJ, there was not too much outside interests who might care if prosecutions were happening, who might care if statewide industry is developing. I think the risk for Oregon — and this is sort of a worst-case scenario — is that pharmaceutical companies can now get involved. They’re the ones who will be legally operating if they follow the final rules produced by the FDA and the standard FDA approval and sales process for pharmaceuticals. Now you have a player beyond just the Department of Justice who could have some interest in owning that market. It certainly injects a concern that now we have real big pharmaceutical interests involved in the cannabis market. And they’re the only ones who can lawfully operate.
Norcross: One of the big problems for the cannabis industry here has been the lack of banking services or tax breaks that other businesses get. Would this move by the federal government this week change any of that?
Margolis: I think it remains to be seen. You know, the banking industry will look at this, federal regulators will look at this, and try and decide if this clears up the legality around the state licensed recreational and medical markets. And I do not believe this move by the Biden administration does that. I don’t believe it legalizes on a federal level what is currently happening in this state. And that is, aside from federal legislation, the path forward to safe banking.
Norcross: You touched on this a little bit earlier, that what the federal government could have done was to treat cannabis like it’s alcohol, and let an entirely different federal agency, the ATF, oversee its use and the regulations around it. I’m wondering if the Biden administration may have missed an opportunity to go all the way and just take it off the schedule of drugs entirely.
Margolis: I think “missed an opportunity” is how the industry will view it. I mean, the industry in Oregon and across the country has been advocating for cannabis to be declassified and not reclassified. And I think the Biden administration knows that and instead chose to go this direction. I think it’s a remnant of the drug war and I think it’s kind of outdated perspectives on cannabis being a hard drug. We’ll see if this is maybe the first step, but I’m concerned that, for the federal government, first steps can last a long time.
Norcross: Do you see any upside for the industry here in Oregon, if cannabis is reclassified in this way?
Margolis: I do think the upside is, you know, we have in the industry been talking about research and cannabis for a long time. And this does open the door to that, which I think will be a positive, even if it’s only a financial benefit to those in the pharmaceutical industry.
Click on the audio player above to hear the whole conversation.
